Altona Diagnostics

Executive Summary

Altona Diagnostics is a German in vitro diagnostics company specializing in PCR-based solutions for pathogen detection, including viruses, bacteria, and parasites. Founded in 1994 and headquartered in Hamburg, the company offers CE-marked IVD kits and research-use-only assays, positioning itself as a PCR expert. Its portfolio addresses infectious diseases with high clinical relevance, leveraging proprietary technology for sensitive and specific molecular testing. As a private entity, Altona has maintained a steady presence in the European market, focusing on regulatory compliance and product reliability. The company's growth prospects are tied to expanding its test menu, entering new geographies, and capitalizing on the increasing demand for molecular diagnostics in infectious disease management. Key opportunities include launching multiplex panels for respiratory infections, seeking FDA approval for entry into the US market, and forming strategic partnerships with global distributors. Despite limited public visibility, Altona's long track record and specialized expertise position it well for moderate growth in the competitive diagnostics landscape.

Upcoming Catalysts (preview)

• Q3 2026CE-mark launch of new multiplex respiratory panel70% success
• Q2 2026FDA clearance for hepatitis B or C diagnostic test50% success
• Q1 2026Strategic distribution partnership for US market entry60% success